Castellano L, Calandra M, Del Vecchio Blanco C, de Sio I
Department of Internal Medicine, II Ateneo University of Naples, Italy.
J Hepatol. 1997 Nov;27(5):862-70. doi: 10.1016/s0168-8278(97)80324-8.
BACKGROUND/AIMS: This study was undertaken to determine the factors predicting survival and intrahepatic recurrence in hepatocellular carcinoma patients treated with percutaneous ethanol injection.
Seventy-one patients with cirrhosis and hepatocellular carcinoma underwent percutaneous ethanol injection (54 males/17 females; median age 66 years; Child A 54/B 17). Fifty-two patients had a single nodule < or = 5 cm and 19 had multiple nodules, up to three, each one < or = 4 cm. Follow-up ranged from 2-63 months (median 26).
Overall survival rates were 89%, 54% and 24% and new lesions recurrence rates 32%, 73% and 81% at 1, 3 and 5 years, respectively. At univariate analysis, monofocal tumor (p<0.05), absence of ascites (p<0.05), complete tumor necrosis at CT-scan or MRI (p<0.01), post-treatment alpha-fetoprotein < or = 10 ng/ml (p<0.05) and Child A class in patients with a single nodule (p<0.05) were associated with higher survival. Presence of tumor capsule at imaging (p<0.05), complete tumor necrosis at CT-scan or MRI (p<0.01) and post-treatment alpha-fetoprotein < or = 10 ng/ml (p<0.01) were associated with lower recurrence rates. At multivariate analysis, basal alpha-fetoprotein (p=0.040) and tumor number (p=0.032) significantly affected survival; stepwise analysis revealed basal alpha-fetoprotein, tumor number and serum albumin (p=0.0012) as the best combination predicting survival. No variable reliably predicted recurrence by multivariate analysis.
In patients with cirrhosis and hepatocellular carcinoma, treated with percutaneous ethanol injection, survival depends on: the severity of the underlying liver disease, uni/multifocality of the tumor and basal alpha-fetoprotein. Presence of a tumor capsule is associated with lower recurrence rates. At post-treatment evaluation, both survival and recurrence rates are positively affected by complete tumor necrosis and alpha-fetoprotein < or = 10 ng/ml.
背景/目的:本研究旨在确定经皮乙醇注射治疗肝细胞癌患者的生存和肝内复发预测因素。
71例肝硬化合并肝细胞癌患者接受经皮乙醇注射治疗(男54例/女17例;中位年龄66岁;Child A级54例/B级17例)。52例患者有单个直径≤5 cm的结节,19例有多个结节,最多3个,每个结节直径≤4 cm。随访时间为2 - 63个月(中位时间26个月)。
1年、3年和5年的总生存率分别为89%、54%和24%,新病灶复发率分别为32%、73%和81%。单因素分析显示,单发病灶(p<0.05)、无腹水(p<0.05)、CT扫描或MRI显示肿瘤完全坏死(p<0.01)、治疗后甲胎蛋白≤10 ng/ml(p<0.05)以及单发病灶患者的Child A级(p<0.05)与较高的生存率相关。影像学检查显示肿瘤有包膜(p<0.05)、CT扫描或MRI显示肿瘤完全坏死(p<0.01)以及治疗后甲胎蛋白≤10 ng/ml(p<0.01)与较低的复发率相关。多因素分析显示,基础甲胎蛋白(p = 0.040)和肿瘤数量(p = 0.032)显著影响生存率;逐步分析显示基础甲胎蛋白、肿瘤数量和血清白蛋白(p = 0.0012)是预测生存率的最佳组合。多因素分析中没有变量能可靠地预测复发。
在接受经皮乙醇注射治疗的肝硬化合并肝细胞癌患者中,生存率取决于:潜在肝病的严重程度、肿瘤的单/多灶性和基础甲胎蛋白。肿瘤有包膜与较低的复发率相关。在治疗后评估中,肿瘤完全坏死和甲胎蛋白≤10 ng/ml对生存率和复发率均有积极影响。